ID   HepAD38
AC   CVCL_M177
SY   Hep AD38; HepG2 AD38; HepG2-AD38; Hep G2 AD 38; AD-38; AD38
DR   BTO; BTO:0006298
DR   cancercelllines; CVCL_M177
DR   Wikidata; Q54882829
RX   Patent=US5723319;
RX   PubMed=9257747;
RX   PubMed=9875378;
RX   PubMed=21331898;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12077.
CC   Population: Caucasian.
CC   Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication.
CC   Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 21
//
RX   Patent=US5723319;
RA   King R.W., Barker C.S., Seeger C.;
RT   "Cultured cell line that inducibly expresses the hepatitis B virus
RT   genome, and uses thereof for screening antiviral substances.";
RL   Patent number US5723319, 03-Mar-1998.
//
RX   PubMed=9257747; DOI=10.1128/AAC.41.8.1715;
RA   Ladner S.K., Otto M.J., Barker C.S., Zaifert K., Wang G.-H.,
RA   Guo J.-T., Seeger C., King R.W.;
RT   "Inducible expression of human hepatitis B virus (HBV) in stably
RT   transfected hepatoblastoma cells: a novel system for screening
RT   potential inhibitors of HBV replication.";
RL   Antimicrob. Agents Chemother. 41:1715-1720(1997).
//
RX   PubMed=9875378;
RA   Ladner S.K., Miller T.J., Otto M.J., King R.W.;
RT   "The hepatitis B virus M539V polymerase variation responsible for 3TC
RT   resistance also confers cross-resistance to other nucleoside
RT   analogues.";
RL   Antivir. Chem. Chemother. 9:65-72(1998).
//
RX   PubMed=21331898; DOI=10.1385/1-59259-245-7:43;
RA   King R.W., Ladner S.K.;
RT   "Hep AD38 assay: a high-throughput, cell-based screen for the
RT   evaluation of compounds against hepatitis B virus.";
RL   Methods Mol. Med. 24:43-50(2000).
//